[ CrossRef ] [ Google scholar ] [ PubMed ] Gruchlik A, Jurzak M, Chodurek E, Dzierzewicz Z
Diet quality, physical activity, sleep optimization, and stress management all influence outcomes
The combined effect leads to improved glycaemic control and significant weight loss
Furthermore, ritlecitinib is contraindicated during pregnancy and lactation, and women of childbearing potential should use effective contraception during therapy and for up to 1 month after discontinuation.17 Clinical evidence for ritlecitinibEfficacy: ALLEGRO phase 2b/3 trial The phase 2b/3 ALLEGRO study (NCT03732807) was a randomized, double-blind, placebo-controlled trial evaluating ritlecitinib in 718 patients aged 12 years with 50% scalp hair loss, assessed using the Severity of Alopecia Tool (SALT) an investigator-rated measure ranging from 0 (no hair loss) to 100 (complete scalp hair loss).8 Patients were randomized to receive 50 or 30mg of ritlecitinib once daily (with or without a 4-week 200mg loading dose regimen), 10mg, or placebo for 24 weeks (Fig
PMID: 37 ThinLTehWL